Zhehai Wang Selected Research

anlotinib

5/2022	The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study.
1/2021	Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial.
1/2020	Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial.
10/2019	The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial.
1/2019	Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303.
11/2018	Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment.
11/2018	Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
1/2018	Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
1/2018	Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zhehai Wang Research Topics

Disease

43	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2024 - 10/2003
20	Neoplasms (Cancer) 12/2023 - 03/2012
7	Disease Progression 05/2024 - 01/2018
5	Adenocarcinoma of Lung 02/2024 - 01/2015
5	Stomach Neoplasms (Stomach Cancer) 01/2018 - 09/2013
4	Neoplasm Metastasis (Metastasis) 05/2024 - 01/2016
4	Hypertension (High Blood Pressure) 01/2021 - 11/2018
3	Lung Neoplasms (Lung Cancer) 01/2024 - 01/2016
3	Diarrhea 01/2022 - 01/2014
2	Exanthema (Rash) 01/2022 - 01/2019
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 01/2019
2	Neutropenia 01/2021 - 01/2014
2	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 01/2014
2	Hand-Foot Syndrome 01/2019 - 11/2018
2	Adenocarcinoma 01/2017 - 05/2016
2	Breast Neoplasms (Breast Cancer) 02/2015 - 02/2013
1	Thrombocytopenia (Thrombopenia) 03/2024
1	Sarcoma (Soft Tissue Sarcoma) 01/2022
1	Thymoma (Thymic Carcinoma) 08/2021
1	Leukopenia 01/2021
1	Hypoxia (Hypoxemia) 01/2021
1	Hypertriglyceridemia 01/2019
1	Hypothyroidism 01/2019
1	Hypersensitivity (Allergy) 01/2019
1	Paronychia 01/2019
1	Hyponatremia 11/2018
1	Lymphopenia (Lymphocytopenia) 01/2018
1	Dyspnea (Shortness of Breath) 01/2018
1	Constipation 01/2018
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2018
1	Malignant Pleural Effusion 01/2018
1	Weight Loss (Weight Reduction) 02/2017
1	Proteinuria 01/2017
1	Esophageal Squamous Cell Carcinoma 01/2016

Drug/Important Bio-Agent (IBA)

9	anlotinibIBA 05/2022 - 01/2018
7	Tyrosine Kinase InhibitorsIBA 05/2024 - 01/2016
6	Immune Checkpoint InhibitorsIBA 01/2024 - 02/2020
6	Biomarkers (Surrogate Marker)IBA 12/2023 - 01/2014
5	apatinibIBA 06/2022 - 09/2013
5	ErbB Receptors (EGF Receptor)IBA 01/2019 - 01/2014
5	Cisplatin (Platino)FDA LinkGeneric 01/2018 - 10/2003
4	Anaplastic Lymphoma KinaseIBA 05/2024 - 01/2018
4	Docetaxel (Taxotere)FDA Link 04/2023 - 02/2017
4	PlatinumIBA 01/2022 - 10/2012
4	Pemetrexed (MTA)FDA Link 01/2021 - 10/2012
3	CrizotinibIBA 05/2024 - 01/2023
3	sintilimabIBA 04/2023 - 01/2021
3	B7-H1 AntigenIBA 01/2023 - 01/2021
3	camrelizumabIBA 12/2022 - 01/2021
3	Fluorouracil (Carac)FDA LinkGeneric 01/2019 - 01/2016
3	Bevacizumab (Avastin)FDA Link 01/2018 - 01/2016
3	AntigensIBA 12/2014 - 03/2012
3	Chimeric Antigen ReceptorsIBA 09/2014 - 03/2012
2	RNA (Ribonucleic Acid)IBA 12/2023 - 12/2021
2	LigandsIBA 12/2022 - 01/2018
2	Gefitinib (Iressa)FDA Link 01/2022 - 02/2015
2	aumolertinibIBA 01/2022 - 01/2022
2	AntibodiesIBA 08/2021 - 01/2019
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2019 - 01/2018
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2019 - 01/2014
2	Leucovorin (Folinic Acid)FDA Link 01/2019 - 01/2018
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2016 - 10/2003
2	Gemcitabine FDA Link 10/2012 - 10/2012
1	alectinibIBA 05/2024
1	serum P-component (CIt)IBA 03/2024
1	oprelvekin (Neumega)FDA Link 03/2024
1	human ERBB2 proteinIBA 01/2024
1	sitravatinibIBA 01/2023
1	tislelizumabIBA 01/2023
1	Programmed Cell Death 1 ReceptorIBA 01/2023
1	Circulating Tumor DNAIBA 12/2022
1	atezolizumabIBA 01/2021
1	Indicators and Reagents (Reagents)IBA 01/2021
1	Carboplatin (JM8)FDA LinkGeneric 01/2021
1	APTIBA 01/2020
1	Antihypertensive Agents (Antihypertensives)IBA 01/2019
1	Thyroxine (Levothyroxine)FDA LinkGeneric 01/2019
1	Cortisone FDA Link 01/2019
1	CMAB009IBA 01/2019
1	Fibric Acids (Fibrates)IBA 01/2019
1	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 11/2018
1	Blood Glucose (Blood Sugar)IBA 11/2018
1	Triglycerides (Triacylglycerol)IBA 11/2018
1	Vinorelbine (Navelbine)FDA LinkGeneric 01/2018
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2018
1	human TNFSF10 proteinIBA 01/2018
1	icotinibIBA 02/2017
1	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 02/2017
1	Mitogen-Activated Protein KinasesIBA 02/2017
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 05/2016
1	Estrogen ReceptorsIBA 02/2015
1	Tamoxifen FDA LinkGeneric 02/2015

Therapy/Procedure

25	Therapeutics 03/2024 - 10/2003
21	Drug Therapy (Chemotherapy) 03/2024 - 05/2002
9	Immunotherapy 03/2024 - 03/2012
3	Radiotherapy 01/2019 - 05/2002
2	Chemoradiotherapy 01/2018 - 01/2016
1	Platelet Transfusion (Blood Platelet Transfusions) 03/2024
1	Precision Medicine 02/2023
1	Folfox protocol 01/2019